HealthQuill US
Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after it scrapped development of its own weight-loss pill in April this year.
Drugs Health Pharma

Pfizer to buy Matsera Inc. for $7.3 billion, eyes 4 anti-obesity drugs

Pfizer Inc. will buy Matsera Inc. for $7.3 billion to eye at least four experimental drugs in the rapidly growing obesity market after.

Read More
Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in females above 12 years and older, weighing at least 40 kilograms.
Drugs Health Pharma

GSK drug gets Britain’s nod to treat UTI patients 12 years and above

Britain’s Medicines and Healthcare products Regulatory Agency has approved GSK Plc’s Blujepa, an oral antibiotic pill to treat uncomplicated urinary tract infections in.

Read More
Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.
Drugs Health Pharma

Biogen’s drug to treat postnatal depression gets UK regulator’s nod

Biogen Inc., a US-based biotechnology company, got a nod from Britain’s medicines regulator for its drug to treat postnatal depression in adults.

Read More
The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious kidney diseases.
Drugs Health Pharma

FDA approves Apellis’ therapy to treat two serious, rare kidney diseases

HQ Team July 30, 2025: The US Food and Drug Administration has approved Apellis Pharmaceuticals, Inc.’s medicine for treating two rare and serious.

Read More
Swedish-British AstraZeneca Plc. plans to build a new facility in the US to manufacture drug components for weight management and metabolism, and invest $50 billion in the country over five years.
Drugs Health Pharma

AstraZeneca to invest $50 billion in US, to build new drug facility

HQ Team July 22, 2025: Swedish-British AstraZeneca Plc. plans to build a new facility in the US to manufacture drug components for weight.

Read More
A patient in Northern Arizona, US, has died from pneumonic plague, the first such death in the country since 2007, according to a government statement.
Drugs Health Pharma

Northern Arizona resident dies of pneumonic plague, first since 2007

HQ Team July 13, 2025: A patient in Northern Arizona, US, has died from pneumonic plague, the first such death in the country.

Read More
Gilead Sciences Inc. and the Global Fund have signed a pact to supply an HIV prevention drug at no profit to benefit two million people in low-income nations.
Drugs Health Pharma

Gilead, Global Fund to supply HIV prevention drug to two million people

HQ Team July 10, 2025: Gilead Sciences Inc. and the Global Fund have signed a pact to supply an HIV prevention drug at.

Read More
Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion to gain access to a respiratory drug approved by the US regulator, according to a statement from Merck.
Drugs Health Pharma

Merck to acquire Verona Pharma for $10 billion to net respiratory drug 

HQ Team July 9, 2025: Merck & Co. will acquire UK-based Verona Pharma Plc for about $10 billion and gain access to a.

Read More
A new and faster method of detecting and measuring radioactivity of tiny amounts of radioactive material has been developed by researchers at the National Institute of Standards and Technology (NIST), America’s national measurement institute.
Health Medical Research

NIST invents new technology to measure tiny radioactive material

HQ Team July 9, 2025: A new and faster method of detecting and measuring radioactivity of tiny amounts of radioactive material has been.

Read More
Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before, and the disease has recurred, has received the US regulator’s green light.
Drugs Health Pharma

Regenron’s drug to treat a type of blood cancer gets US regulator’s nod

HQ Team June 3, 2025: Regeneron Pharmaceuticals, Inc.’s drug for a type of blood cancer in patients who have received four treatments before,.

Read More